Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si Incorporated plans to report its second quarter 2021 financial results on August 12, 2021, prior to market opening. CEO John Stark and CFO Claudia Drayton will hold a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. The call can be accessed via a live webcast on the company's Investor Relations website. Quantum-Si is focused on advancing proteomics through innovative semiconductor technology for protein sequencing.
Quantum-Si Incorporated has signed a lease with Phase 3 Real Estate Partners for a 25,586-square-foot facility in San Diego, CA. This site will enhance its product development and R&D capabilities, crucial for recruiting talent and commercial readiness in the proteomics market. Operations are anticipated to commence in Q3 2021. CEO John Stark emphasized the facility's role in scaling operations to meet the growing demand for protein sequencing technologies, which are expected to revolutionize drug discovery and diagnostics.
Quantum-Si Incorporated (Nasdaq: QSI) has successfully completed its business combination with HighCape Capital Acquisition Corp. (Nasdaq: CAPA), resulting in over $500 million for the development of its semiconductor chip-based protein sequencing technology. The combined company, now trading as Quantum-Si, aims to disrupt the $21 billion academic research and drug discovery market with its unique end-to-end solution. The company’s leadership includes experienced executives and it anticipates launching its products commercially in 2022.